|
|
News Breaks | | | | January 25, 2013 | | 05:18 EDT |  | THLD | Threshold Pharmaceuticals initiates Phase 3 MAESTRO study for TH-302
Threshold Pharmaceuticals announced that Threshold's partner Merck KGaA, Darmstadt, Germany, through its division Merck Serono, initiated the global Phase 3 MAESTRO study assessing the efficacy and safety of investigational hypoxia-targeted drug TH-302 in combination with gemcitabine in patients with previously untreated, locally advanced unresectable or metastatic pancreatic adenocarcinoma. The initiation of the Phase 3 MAESTRO study resulted in Threshold earning a $30M milestone payment from Merck KGaA pursuant to the terms of Threshold's license and co-development agreement with Merck KGaA, which includes an option for Threshold to co-commercialize in the U.S. MAESTRO stands for TH-302 in the treatment of MetastAtic or unrESectable pancreaTic adenocaRcinOma. | |
|
News For THLD From The Last 14 Days Check below for free stories on THLD the last two weeks. |
|
|
| May 22, 2013 | | 07:28 EDT |  | THLD | UBS to host a conference
Global Healthcare Services Conference is being held in New York on May 20-22 with webcasted company presentations to begin on May 22 at 8 am; not all company presentations may be webcasted. Webcast Link | |
|
|
|
|
|
|
